F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: A novel mode of kinase inhibitor resistance

Leukemia

Volumn 29, Issue 8, 2015, Pages 1763-1770

  Gorantla, S P ^a,b   Zirlik, K ^a   Reiter, A ^c   Yu, C ^a   Illert, A L ^a   Von Bubnoff, N ^a   Duyster, J ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIP1L1 PDGFRA PROTEIN; HYBRID PROTEIN; IMATINIB; PHENYLALANINE; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SERINE; UNCLASSIFIED DRUG; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE INHIBITOR; PTPN11 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; BONE MARROW CELL; CANCER RESISTANCE; CELL GROWTH; CONTROLLED STUDY; DRUG BINDING; ENZYME INHIBITION; GENE MUTATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN TARGETING; 3T3 CELL LINE; ANIMAL; APOPTOSIS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; HYPEREOSINOPHILIC SYNDROME; METABOLISM; MUTATION; PRE B LYMPHOCYTE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; HEK293 CELLS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MICE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; NIH 3T3 CELLS; ONCOGENE PROTEIN PP60(V-SRC); ONCOGENE PROTEINS, FUSION; PRECURSOR CELLS, B-LYMPHOID; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84938963775     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.70     Document Type: Article

References (37)

1. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891.
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
3. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179.
4. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038-3045.
5. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30: 965-970.
6. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999-2010.
7. Erben P, Gosenca D, Muller MC, Reinhard J, Score J, Del Valle F et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010; 95: 738-744.
8. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011; 117: 2935-2943.
9. Buitenhuis M, Verhagen LP, Cools J, Coffer PJ. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007; 67: 3759-3766.
10. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003; 3: 459-469.
11. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hyper-eosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006; 107: 4071-4079.
12. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK et al. Oligo-merization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996; 16: 4107-4116.
13. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006; 103: 8078-8083.
14. Ohnishi H, Kandabashi K, Maeda Y, Kawamura M, Watanabe T. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006; 134: 547-549.
15. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19: 286-287.
16. Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23: 845-851.
17. von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thone S, Aberg E et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 2011; 30: 933-943.
18. Bai RY, Jahn T, Schrem S, Munzert G, Weidner KM, Wang JY et al. The SH2-containing adapter protein GRB10 interacts with BCR-ABL. Oncogene 1998; 17: 941-948.
19. Jahn T, Seipel P, Urschel S, Peschel C, Duyster J. Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biology 2002; 22: 979-991.
20. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005; 105: 4792-4799.
21. Duyster J, Baskaran R, Wang JY. Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc Natl Acad Sci USA 1995; 92: 1555-1559.
22. Rosenkranz S, Ikuno Y, Leong FL, Klinghoffer RA, Miyake S, Band H et al. Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J Biol Chem 2000; 275: 9620-9627.
23. Avrov K, Kazlauskas A. The role of c-Src in platelet-derived growth factor alpha receptor internalization. Exp Cell Res 2003; 291: 426-434.
24. Vantler M, Huntgeburth M, Caglayan E, Ten Freyhaus H, Schnabel P, Rosenkranz S et al. PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases. FEBS Lett 2006; 580: 6769-6776.
25. Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 1999; 274: 16619-16628.
26. Bazenet CE, Gelderloos JA, Kazlauskas A. Phosphorylation of tyrosine 720 in the platelet-derived growth factor alpha receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation. Mol Cell Biol 1996; 16: 6926-6936.
27. Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 2009; 64: 913-918.
28. Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H et al. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene 2002; 21: 1423-1433.
29. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92: 441-450.
30. Lu W, Gong D, Bar-Sagi D, Cole PA. Site-specific incorporation of a phos-photyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol cell 2001; 8: 759-769.
31. Kazlauskas A, Feng GS, Pawson T, Valius M. The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. Proc Natl Acad Sci USA 1993; 90: 6939-6943.
32. Maegawa H, Ugi S, Ishibashi O, Tachikawa-Ide R, Takahara N, Tanaka Y et al. Src homology 2 domains of protein tyrosine phosphatase are phosphorylated by insulin receptor kinase and bind to the COOH-terminus of insulin receptors in vitro. Biochem Biophys Res Commun 1993; 194: 208-214.
33. Uchida T, Matozaki T, Noguchi T, Yamao T, Horita K, Suzuki T et al. Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains. J Biol Chem 1994; 269: 12220-12228.
34. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-843.
35. Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia 2013; 27: 2254-2256.
36. Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012; 26: 162-164.
37. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008; 143: 707-715.